新华鲜报|更贴近患者！药品集采新规则发布

Core Viewpoint - The recent adjustments to the national drug procurement rules aim to enhance the balance between drug supply and demand, ensuring that patients have access to high-quality and affordable medications while supporting the development of the pharmaceutical industry [1][7]. Group 1: Supply and Demand Matching - Over 46,000 medical institutions participated in the latest round of national drug procurement, with nearly 80% specifying the required brands, indicating improved matching between drug supply and clinical demand [3]. - The agreed procurement volume for medical institutions is typically 80%, but for certain special categories, this will be reduced to 60-70% [3]. - New rules allow for "revival" opportunities for non-selected companies if they can accept the winning bid prices, enhancing competition [3][4]. Group 2: Quality Assurance - The new rules raise the quality standards for bidding companies, requiring at least two years of production experience for similar dosage forms and compliance with Good Manufacturing Practices (GMP) [3][4]. - Companies with the same bid price will be prioritized based on their production stability and absence of significant changes in production processes or raw materials [4]. Group 3: Anti-Collusion Measures - The rules address collusion by treating closely linked companies as a single entity during bidding, with strict penalties for collusion and a new "first report leniency" mechanism for whistleblowers [6]. - This aims to dismantle the interests of colluding companies and promote fair competition [6]. Group 4: Competition Regulation - To prevent excessive competition, the rules introduce price control measures, including a minimum price threshold and a commitment from bidders not to undercut their costs [6]. - The overall selection rate for this procurement round remains stable at around 60%, with potential increases due to the new revival rules [6]. Group 5: Transparency and Patient Focus - The adjustments were made after extensive consultations, emphasizing the goal of providing patients with high-quality and affordable medications [7]. - The trend towards greater transparency in procurement processes is expected to continue, ensuring that drug prices reflect their value and that patients can use medications with confidence [7].